177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2010-10

AUTHORS

Daniel Hubble, Grace Kong, Michael Michael, Val Johnson, Shakher Ramdave, Rodney John Hicks

ABSTRACT

PURPOSE: The aim of this retrospective study was to determine whether patients with previous peptide receptor radionuclide therapy using high-activity (111)In-pentetreotide can be safely treated with (177)Lu-octreotate and whether addition of radiosensitising chemotherapy increases the toxicity of this agent. METHODS: Records of 27 patients (aged 17-75) who received 69 (median 3 per patient) (177)Lu-octreotate administrations, including 29 in conjunction with radiosensitising infusional 5-fluorouracil (5-FU) (n = 27), or capecitabine (n = 2), between October 2005 and July 2007 subsequent to 1-8 prior cycles of (111)In-pentetreotide therapy were analysed. Toxicity was assessed during and at 8-12 weeks post-treatment, with further long-term assessments including survival status reviewed till death or study close-out date of 1 November 2009. RESULTS: Reduction in blood counts was most marked following the first dose of (177)Lu-octreotate but at early follow-up the only major haematological toxicity was a single case of grade 4 lymphopaenia. Both the presence of bone metastases and the administration of chemotherapy tended to result in greater reduction in blood counts, but these differences did not reach statistical significance. On long-term follow-up, 16 patients (59%) are alive with median overall survival of 36 months (32-44 months from first (177)Lu-octreotate therapy). None of the recorded deaths was directly related to treatment toxicity. One patient had late grade 4 anaemia and thrombocytopaenia secondary to bone marrow failure from progressive infiltration by tumour. No other significant long-term haematological toxicities were recorded and no leukaemia was observed. No renal toxicity was observed on serial serum creatinine or radionuclide glomerular filtration rate (GFR) determination on initial or long-term follow-up. CONCLUSION: (177)Lu-octreotate is a safe and well-tolerated therapy for patients who have previously been treated with (111)In-pentetreotide and can be safely combined with radiosensitising chemotherapy. However, caution is recommended in patients with bone metastases. Significant late toxicities including bone marrow or renal failure, or leukaemia directly related to radionuclide therapy, did not occur in our series. More... »

PAGES

1869-1875

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00259-010-1483-4

DOI

http://dx.doi.org/10.1007/s00259-010-1483-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1052925405

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/20445977


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Capecitabine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Deoxycytidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorouracil", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hematologic Tests", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neuroendocrine Tumors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Octreotide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Organometallic Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prodrugs", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radiation-Sensitizing Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Peptide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Peter MacCallum Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.1055.1", 
          "name": [
            "Centre for Molecular Imaging, Peter MacCallum Cancer Centre, 12 St Andrew\u2019s Place, 3002, East Melbourne, VIC, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hubble", 
        "givenName": "Daniel", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peter MacCallum Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.1055.1", 
          "name": [
            "Centre for Molecular Imaging, Peter MacCallum Cancer Centre, 12 St Andrew\u2019s Place, 3002, East Melbourne, VIC, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kong", 
        "givenName": "Grace", 
        "id": "sg:person.01122451566.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01122451566.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peter MacCallum Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.1055.1", 
          "name": [
            "Centre for Molecular Imaging, Peter MacCallum Cancer Centre, 12 St Andrew\u2019s Place, 3002, East Melbourne, VIC, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Michael", 
        "givenName": "Michael", 
        "id": "sg:person.0673420201.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673420201.89"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peter MacCallum Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.1055.1", 
          "name": [
            "Centre for Molecular Imaging, Peter MacCallum Cancer Centre, 12 St Andrew\u2019s Place, 3002, East Melbourne, VIC, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Johnson", 
        "givenName": "Val", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peter MacCallum Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.1055.1", 
          "name": [
            "Centre for Molecular Imaging, Peter MacCallum Cancer Centre, 12 St Andrew\u2019s Place, 3002, East Melbourne, VIC, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ramdave", 
        "givenName": "Shakher", 
        "id": "sg:person.01236700166.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01236700166.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Peter MacCallum Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.1055.1", 
          "name": [
            "Centre for Molecular Imaging, Peter MacCallum Cancer Centre, 12 St Andrew\u2019s Place, 3002, East Melbourne, VIC, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hicks", 
        "givenName": "Rodney John", 
        "id": "sg:person.01121233254.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01121233254.97"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1093/annonc/10.suppl_2.s31", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003031999"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.22.8510", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006418900"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1053/snuc.2002.31769", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011217908"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00259-007-0688-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016804176", 
          "https://doi.org/10.1007/s00259-007-0688-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00259-007-0688-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016804176", 
          "https://doi.org/10.1007/s00259-007-0688-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.15.2553", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019213889"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002590050216", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022226125", 
          "https://doi.org/10.1007/s002590050216"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1053/snuc/2002.31025", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031251521"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002590100574", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045446163", 
          "https://doi.org/10.1007/s002590100574"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00259-002-1050-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045597456", 
          "https://doi.org/10.1007/s00259-002-1050-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00259-002-1050-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045597456", 
          "https://doi.org/10.1007/s00259-002-1050-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.beem.2007.01.004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046292579"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00259-002-0982-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046951944", 
          "https://doi.org/10.1007/s00259-002-0982-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002590050476", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049195855", 
          "https://doi.org/10.1007/s002590050476"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1089/cbr.2009.0641", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059242984"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1089/cbr.2009.0644", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059242987"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1667/0033-7587(2003)159[0182:tnoadi]2.0.co;2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1068194847"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075047030", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1076862224", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077094736", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082648707", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2010-10", 
    "datePublishedReg": "2010-10-01", 
    "description": "PURPOSE: The aim of this retrospective study was to determine whether patients with previous peptide receptor radionuclide therapy using high-activity (111)In-pentetreotide can be safely treated with (177)Lu-octreotate and whether addition of radiosensitising chemotherapy increases the toxicity of this agent.\nMETHODS: Records of 27 patients (aged 17-75) who received 69 (median 3 per patient) (177)Lu-octreotate administrations, including 29 in conjunction with radiosensitising infusional 5-fluorouracil (5-FU) (n = 27), or capecitabine (n = 2), between October 2005 and July 2007 subsequent to 1-8 prior cycles of (111)In-pentetreotide therapy were analysed. Toxicity was assessed during and at 8-12 weeks post-treatment, with further long-term assessments including survival status reviewed till death or study close-out date of 1 November 2009.\nRESULTS: Reduction in blood counts was most marked following the first dose of (177)Lu-octreotate but at early follow-up the only major haematological toxicity was a single case of grade 4 lymphopaenia. Both the presence of bone metastases and the administration of chemotherapy tended to result in greater reduction in blood counts, but these differences did not reach statistical significance. On long-term follow-up, 16 patients (59%) are alive with median overall survival of 36 months (32-44 months from first (177)Lu-octreotate therapy). None of the recorded deaths was directly related to treatment toxicity. One patient had late grade 4 anaemia and thrombocytopaenia secondary to bone marrow failure from progressive infiltration by tumour. No other significant long-term haematological toxicities were recorded and no leukaemia was observed. No renal toxicity was observed on serial serum creatinine or radionuclide glomerular filtration rate (GFR) determination on initial or long-term follow-up.\nCONCLUSION: (177)Lu-octreotate is a safe and well-tolerated therapy for patients who have previously been treated with (111)In-pentetreotide and can be safely combined with radiosensitising chemotherapy. However, caution is recommended in patients with bone metastases. Significant late toxicities including bone marrow or renal failure, or leukaemia directly related to radionuclide therapy, did not occur in our series.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00259-010-1483-4", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1297401", 
        "issn": [
          "1619-7070", 
          "1619-7089"
        ], 
        "name": "European Journal of Nuclear Medicine and Molecular Imaging", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "10", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "37"
      }
    ], 
    "name": "177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide", 
    "pagination": "1869-1875", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "fc19567beae7d3f42c2327fb162c4270a37561a9a654f5cce2792363e7389a35"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "20445977"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101140988"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00259-010-1483-4"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1052925405"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00259-010-1483-4", 
      "https://app.dimensions.ai/details/publication/pub.1052925405"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T10:33", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000349_0000000349/records_113661_00000002.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs00259-010-1483-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00259-010-1483-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00259-010-1483-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00259-010-1483-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00259-010-1483-4'


 

This table displays all metadata directly associated to this object as RDF triples.

257 TRIPLES      21 PREDICATES      72 URIs      45 LITERALS      33 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00259-010-1483-4 schema:about N0d533c9ffc584f5f9ff08281d52d35a4
2 N0f0f1376e9264f29a78687496e439b3c
3 N12153289148f4f049cd99ca838a0969b
4 N12e864cae80e4c13866a324a18c13ad0
5 N17045196b1a64a13af20a2975183c2f2
6 N1ae22b6136c7431dac17895977471bf9
7 N1af7579f609c4d3c91b997878af81809
8 N1dbad5bc2f36461d9fc154902ec88c5d
9 N272b4ff16b19453da7374738b1be1a05
10 N34aff052bd3a495db9966263623f5a09
11 N3d480bcc5e9b4174aa40851f7e107aad
12 N3f65bfbdc09140ca80079f3fcf3cb12e
13 N41f098c1d7b84a2ba6053c43403dfa32
14 N492f915efb2d4a4c9dedf916a33c12f4
15 N4e64b27c0ebc4f4aa83f6321db122753
16 N5fe734a7a2e3479da8b3ee9c2e81f9b2
17 N66ac7491d9b84e38aca11ffe9fdad67d
18 N787b423a95bf4caaab7eaede38344462
19 N8387f509c1794dcd9e0162dd284ffdab
20 N9800d32ae1524f3e9436bd7b95c60791
21 N9e8d19f369594253aaface6e2b27738f
22 Nc3fefc5c172e49b99b544a446b8024de
23 Ncae91973acb849679f6ff0bfc110a6e0
24 Nf2de1fc494e34df4a7606867b69487c7
25 anzsrc-for:11
26 anzsrc-for:1103
27 schema:author Nd13ec08356dc44bc9bb7d3816a9da771
28 schema:citation sg:pub.10.1007/s00259-002-0982-3
29 sg:pub.10.1007/s00259-002-1050-8
30 sg:pub.10.1007/s00259-007-0688-7
31 sg:pub.10.1007/s002590050216
32 sg:pub.10.1007/s002590050476
33 sg:pub.10.1007/s002590100574
34 https://app.dimensions.ai/details/publication/pub.1075047030
35 https://app.dimensions.ai/details/publication/pub.1076862224
36 https://app.dimensions.ai/details/publication/pub.1077094736
37 https://app.dimensions.ai/details/publication/pub.1082648707
38 https://doi.org/10.1016/j.beem.2007.01.004
39 https://doi.org/10.1053/snuc.2002.31769
40 https://doi.org/10.1053/snuc/2002.31025
41 https://doi.org/10.1089/cbr.2009.0641
42 https://doi.org/10.1089/cbr.2009.0644
43 https://doi.org/10.1093/annonc/10.suppl_2.s31
44 https://doi.org/10.1200/jco.2007.15.2553
45 https://doi.org/10.1200/jco.2009.22.8510
46 https://doi.org/10.1667/0033-7587(2003)159[0182:tnoadi]2.0.co;2
47 schema:datePublished 2010-10
48 schema:datePublishedReg 2010-10-01
49 schema:description PURPOSE: The aim of this retrospective study was to determine whether patients with previous peptide receptor radionuclide therapy using high-activity (111)In-pentetreotide can be safely treated with (177)Lu-octreotate and whether addition of radiosensitising chemotherapy increases the toxicity of this agent. METHODS: Records of 27 patients (aged 17-75) who received 69 (median 3 per patient) (177)Lu-octreotate administrations, including 29 in conjunction with radiosensitising infusional 5-fluorouracil (5-FU) (n = 27), or capecitabine (n = 2), between October 2005 and July 2007 subsequent to 1-8 prior cycles of (111)In-pentetreotide therapy were analysed. Toxicity was assessed during and at 8-12 weeks post-treatment, with further long-term assessments including survival status reviewed till death or study close-out date of 1 November 2009. RESULTS: Reduction in blood counts was most marked following the first dose of (177)Lu-octreotate but at early follow-up the only major haematological toxicity was a single case of grade 4 lymphopaenia. Both the presence of bone metastases and the administration of chemotherapy tended to result in greater reduction in blood counts, but these differences did not reach statistical significance. On long-term follow-up, 16 patients (59%) are alive with median overall survival of 36 months (32-44 months from first (177)Lu-octreotate therapy). None of the recorded deaths was directly related to treatment toxicity. One patient had late grade 4 anaemia and thrombocytopaenia secondary to bone marrow failure from progressive infiltration by tumour. No other significant long-term haematological toxicities were recorded and no leukaemia was observed. No renal toxicity was observed on serial serum creatinine or radionuclide glomerular filtration rate (GFR) determination on initial or long-term follow-up. CONCLUSION: (177)Lu-octreotate is a safe and well-tolerated therapy for patients who have previously been treated with (111)In-pentetreotide and can be safely combined with radiosensitising chemotherapy. However, caution is recommended in patients with bone metastases. Significant late toxicities including bone marrow or renal failure, or leukaemia directly related to radionuclide therapy, did not occur in our series.
50 schema:genre research_article
51 schema:inLanguage en
52 schema:isAccessibleForFree false
53 schema:isPartOf N01b39fe626c3499eacf0e65c8f1ecd51
54 Nf64a843842a245c2b5da5be38816e7cd
55 sg:journal.1297401
56 schema:name 177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide
57 schema:pagination 1869-1875
58 schema:productId N08ec105c21404fd3b05ccceb587af5b4
59 N1b856a79324046be9bfc12434745d94c
60 N72b82ecb6e91489e802be55fd0f1860d
61 Nbee96ccaaba14b4797f2cfa27d659707
62 Ne03b9f870c9d40809321fc3ed15527a5
63 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052925405
64 https://doi.org/10.1007/s00259-010-1483-4
65 schema:sdDatePublished 2019-04-11T10:33
66 schema:sdLicense https://scigraph.springernature.com/explorer/license/
67 schema:sdPublisher N68dd4ae5378a4585bb4259ee27ad507c
68 schema:url http://link.springer.com/10.1007%2Fs00259-010-1483-4
69 sgo:license sg:explorer/license/
70 sgo:sdDataset articles
71 rdf:type schema:ScholarlyArticle
72 N01b39fe626c3499eacf0e65c8f1ecd51 schema:issueNumber 10
73 rdf:type schema:PublicationIssue
74 N08ec105c21404fd3b05ccceb587af5b4 schema:name doi
75 schema:value 10.1007/s00259-010-1483-4
76 rdf:type schema:PropertyValue
77 N0c8034b6e67746b2851523691fc40030 rdf:first sg:person.01121233254.97
78 rdf:rest rdf:nil
79 N0d533c9ffc584f5f9ff08281d52d35a4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Male
81 rdf:type schema:DefinedTerm
82 N0f0f1376e9264f29a78687496e439b3c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Organometallic Compounds
84 rdf:type schema:DefinedTerm
85 N12153289148f4f049cd99ca838a0969b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Humans
87 rdf:type schema:DefinedTerm
88 N12e864cae80e4c13866a324a18c13ad0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Radiation-Sensitizing Agents
90 rdf:type schema:DefinedTerm
91 N17045196b1a64a13af20a2975183c2f2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Deoxycytidine
93 rdf:type schema:DefinedTerm
94 N1821342f4cb145b3830353f5f4709a49 schema:affiliation https://www.grid.ac/institutes/grid.1055.1
95 schema:familyName Hubble
96 schema:givenName Daniel
97 rdf:type schema:Person
98 N1ae22b6136c7431dac17895977471bf9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Young Adult
100 rdf:type schema:DefinedTerm
101 N1af7579f609c4d3c91b997878af81809 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Receptors, Peptide
103 rdf:type schema:DefinedTerm
104 N1b856a79324046be9bfc12434745d94c schema:name nlm_unique_id
105 schema:value 101140988
106 rdf:type schema:PropertyValue
107 N1dbad5bc2f36461d9fc154902ec88c5d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Retrospective Studies
109 rdf:type schema:DefinedTerm
110 N272b4ff16b19453da7374738b1be1a05 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Aged
112 rdf:type schema:DefinedTerm
113 N34aff052bd3a495db9966263623f5a09 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Adult
115 rdf:type schema:DefinedTerm
116 N3d480bcc5e9b4174aa40851f7e107aad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Survival Analysis
118 rdf:type schema:DefinedTerm
119 N3f65bfbdc09140ca80079f3fcf3cb12e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Antineoplastic Combined Chemotherapy Protocols
121 rdf:type schema:DefinedTerm
122 N41f098c1d7b84a2ba6053c43403dfa32 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Fluorouracil
124 rdf:type schema:DefinedTerm
125 N492f915efb2d4a4c9dedf916a33c12f4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Time Factors
127 rdf:type schema:DefinedTerm
128 N4a0ec34945994fce86baea91a4943710 schema:affiliation https://www.grid.ac/institutes/grid.1055.1
129 schema:familyName Johnson
130 schema:givenName Val
131 rdf:type schema:Person
132 N4e64b27c0ebc4f4aa83f6321db122753 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Neuroendocrine Tumors
134 rdf:type schema:DefinedTerm
135 N5fe734a7a2e3479da8b3ee9c2e81f9b2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Middle Aged
137 rdf:type schema:DefinedTerm
138 N626ec2e713b7480bb113fb5e3068dbc2 rdf:first N4a0ec34945994fce86baea91a4943710
139 rdf:rest N9e827c75c09a446cba6df04067f3d391
140 N66ac7491d9b84e38aca11ffe9fdad67d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Octreotide
142 rdf:type schema:DefinedTerm
143 N68dd4ae5378a4585bb4259ee27ad507c schema:name Springer Nature - SN SciGraph project
144 rdf:type schema:Organization
145 N72b82ecb6e91489e802be55fd0f1860d schema:name dimensions_id
146 schema:value pub.1052925405
147 rdf:type schema:PropertyValue
148 N787b423a95bf4caaab7eaede38344462 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Hematologic Tests
150 rdf:type schema:DefinedTerm
151 N8387f509c1794dcd9e0162dd284ffdab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Adolescent
153 rdf:type schema:DefinedTerm
154 N9800d32ae1524f3e9436bd7b95c60791 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Capecitabine
156 rdf:type schema:DefinedTerm
157 N9bcf9a7913f143f69b131569335770d5 rdf:first sg:person.0673420201.89
158 rdf:rest N626ec2e713b7480bb113fb5e3068dbc2
159 N9e827c75c09a446cba6df04067f3d391 rdf:first sg:person.01236700166.42
160 rdf:rest N0c8034b6e67746b2851523691fc40030
161 N9e8d19f369594253aaface6e2b27738f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Prodrugs
163 rdf:type schema:DefinedTerm
164 Nbee96ccaaba14b4797f2cfa27d659707 schema:name pubmed_id
165 schema:value 20445977
166 rdf:type schema:PropertyValue
167 Nc3fefc5c172e49b99b544a446b8024de schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Kidney
169 rdf:type schema:DefinedTerm
170 Ncae91973acb849679f6ff0bfc110a6e0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Female
172 rdf:type schema:DefinedTerm
173 Nd13ec08356dc44bc9bb7d3816a9da771 rdf:first N1821342f4cb145b3830353f5f4709a49
174 rdf:rest Ndcdac0713e844449843437bebb4f010d
175 Ndcdac0713e844449843437bebb4f010d rdf:first sg:person.01122451566.24
176 rdf:rest N9bcf9a7913f143f69b131569335770d5
177 Ne03b9f870c9d40809321fc3ed15527a5 schema:name readcube_id
178 schema:value fc19567beae7d3f42c2327fb162c4270a37561a9a654f5cce2792363e7389a35
179 rdf:type schema:PropertyValue
180 Nf2de1fc494e34df4a7606867b69487c7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Follow-Up Studies
182 rdf:type schema:DefinedTerm
183 Nf64a843842a245c2b5da5be38816e7cd schema:volumeNumber 37
184 rdf:type schema:PublicationVolume
185 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
186 schema:name Medical and Health Sciences
187 rdf:type schema:DefinedTerm
188 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
189 schema:name Clinical Sciences
190 rdf:type schema:DefinedTerm
191 sg:journal.1297401 schema:issn 1619-7070
192 1619-7089
193 schema:name European Journal of Nuclear Medicine and Molecular Imaging
194 rdf:type schema:Periodical
195 sg:person.01121233254.97 schema:affiliation https://www.grid.ac/institutes/grid.1055.1
196 schema:familyName Hicks
197 schema:givenName Rodney John
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01121233254.97
199 rdf:type schema:Person
200 sg:person.01122451566.24 schema:affiliation https://www.grid.ac/institutes/grid.1055.1
201 schema:familyName Kong
202 schema:givenName Grace
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01122451566.24
204 rdf:type schema:Person
205 sg:person.01236700166.42 schema:affiliation https://www.grid.ac/institutes/grid.1055.1
206 schema:familyName Ramdave
207 schema:givenName Shakher
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01236700166.42
209 rdf:type schema:Person
210 sg:person.0673420201.89 schema:affiliation https://www.grid.ac/institutes/grid.1055.1
211 schema:familyName Michael
212 schema:givenName Michael
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673420201.89
214 rdf:type schema:Person
215 sg:pub.10.1007/s00259-002-0982-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046951944
216 https://doi.org/10.1007/s00259-002-0982-3
217 rdf:type schema:CreativeWork
218 sg:pub.10.1007/s00259-002-1050-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045597456
219 https://doi.org/10.1007/s00259-002-1050-8
220 rdf:type schema:CreativeWork
221 sg:pub.10.1007/s00259-007-0688-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016804176
222 https://doi.org/10.1007/s00259-007-0688-7
223 rdf:type schema:CreativeWork
224 sg:pub.10.1007/s002590050216 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022226125
225 https://doi.org/10.1007/s002590050216
226 rdf:type schema:CreativeWork
227 sg:pub.10.1007/s002590050476 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049195855
228 https://doi.org/10.1007/s002590050476
229 rdf:type schema:CreativeWork
230 sg:pub.10.1007/s002590100574 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045446163
231 https://doi.org/10.1007/s002590100574
232 rdf:type schema:CreativeWork
233 https://app.dimensions.ai/details/publication/pub.1075047030 schema:CreativeWork
234 https://app.dimensions.ai/details/publication/pub.1076862224 schema:CreativeWork
235 https://app.dimensions.ai/details/publication/pub.1077094736 schema:CreativeWork
236 https://app.dimensions.ai/details/publication/pub.1082648707 schema:CreativeWork
237 https://doi.org/10.1016/j.beem.2007.01.004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046292579
238 rdf:type schema:CreativeWork
239 https://doi.org/10.1053/snuc.2002.31769 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011217908
240 rdf:type schema:CreativeWork
241 https://doi.org/10.1053/snuc/2002.31025 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031251521
242 rdf:type schema:CreativeWork
243 https://doi.org/10.1089/cbr.2009.0641 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059242984
244 rdf:type schema:CreativeWork
245 https://doi.org/10.1089/cbr.2009.0644 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059242987
246 rdf:type schema:CreativeWork
247 https://doi.org/10.1093/annonc/10.suppl_2.s31 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003031999
248 rdf:type schema:CreativeWork
249 https://doi.org/10.1200/jco.2007.15.2553 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019213889
250 rdf:type schema:CreativeWork
251 https://doi.org/10.1200/jco.2009.22.8510 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006418900
252 rdf:type schema:CreativeWork
253 https://doi.org/10.1667/0033-7587(2003)159[0182:tnoadi]2.0.co;2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1068194847
254 rdf:type schema:CreativeWork
255 https://www.grid.ac/institutes/grid.1055.1 schema:alternateName Peter MacCallum Cancer Centre
256 schema:name Centre for Molecular Imaging, Peter MacCallum Cancer Centre, 12 St Andrew’s Place, 3002, East Melbourne, VIC, Australia
257 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...